



BIOFIRE® RESPIRATORY 2.1 PLUS (RP2.1plus) PANEL

1 Test. 23 Targets. ~45 Minutes.

VIRUSES

Adenovirus
Coronavirus 229E
Coronavirus HKU1
Coronavirus NL63
Coronavirus OC43
Middle East respiratory syndrome coronavirus (MERS-CoV)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Human metapneumovirus
Human rhinovirus/enterovirus

Influenza A virus
Influenza A virus A/H1
Influenza A virus A/H3
Influenza A virus A/H1-2009
Influenza B virus
Parainfluenza virus 1
Parainfluenza virus 2
Parainfluenza virus 3
Parainfluenza virus 4
Respiratory syncytial virus

BACTERIA

Bordetella parapertussis
Bordetella pertussis
Chlamydia pneumoniae
Mycoplasma pneumoniae

Overall Performance: 97.1% sensitivity, 99.3% specificity¹
SARS-CoV-2 Performance: 98.4% PPA, 98.9% NPA²

CE₂₇₉₇

Fast. Easy. Comprehensive.

Syndromic testing provides a streamlined workflow and fast, comprehensive results.



0.3mL of
nasopharyngeal swab in
transport media or saline



2 minutes
hands-on time



Results in about
45 minutes




Comprehensive
results in a single
report



**Improved Patient
Management³⁻⁹**

Knowing the Pathogen Matters



Inform Clinical Decisions

Respiratory infections can be characterized by similar symptoms, making diagnosis difficult. The BIOFIRE® Respiratory 2.1 (RP2.1) Panel* was shown to increase diagnostic yield by more than 50%, compared to traditional testing methods.⁵



Reduce Length of Stay

The hospital length of stay was nearly 5 days less for febrile infants with a positive BIOFIRE RP2.1 Panel* result compared to those with a negative result.⁴



**OPTIMIZE DIAGNOSTICS.
OPTIMIZE THERAPY.**
With our complete solution
for antimicrobial stewardship.

Reduce Antibiotic Use

The BIOFIRE RP2.1 Panel* resulted in avoidance of antibiotics in 23% of pediatric patients tested.⁹

Is it COVID-19? The Flu? Or Something Else?

Identifying respiratory pathogens has never been more urgent. But several respiratory pathogens can cause similar, overlapping symptoms. Data from BIOFIRE® FIREWORKS™ demonstrates that even during conventional flu season, influenza comprised less than one third of detected respiratory pathogens during this period. A comprehensive panel means fewer missed detections.



Panel Information

Sample Type: nasopharyngeal swab in transport media or saline

Storage Conditions: all kit components stored at room temperature (15-25 °C)

BIOFIRE RP2.1plus Panel Reagent Kit (30 Pouches): 423740



Scan the QR code
for more information.

Learn more about the BIOFIRE range of commercially-available panels for syndromic infectious disease diagnostics.



Contact Us

bioMérieux S.A.
69280 Marcy l'Etoile
France
Tel: +33 (0) 4 78 87 20 00
Fax: +33 (0) 4 78 87 20 90
biomerieux.com

Manufactured by:
BioFire Diagnostics, LLC
515 Colorow Drive
Salt Lake City, UT 84108 USA
Tel: +1-801-736-6354

References

1. Overall performance based on prospective clinical study for the BIOFIRE® Respiratory 2 plus Panel, data on file, BioFire Diagnostics.
2. Overall performance based on prospective SARS-CoV-2 clinical study for the BIOFIRE® Respiratory 2.1 plus Panel in comparison to 3 EUA tests, data on file, BioFire Diagnostics.
3. Lee BR, et al. J Clin Virol. 2019;110:11-16. doi:10.1016/j.jcv.2018.11.006.
4. McFall, et al., Pediatrics. 2017 Feb;:000992281774066.
5. Kitano, Taito et al. J Infect Chemother. 2020;26(1):82-85. doi:10.1016/j.jiac.2019.07.014.
6. Gelfer G, et al. Diag Micro Infect Dis. 2015;83:400-406.
7. Rappo U, et al. J. Clin. Microbiol. JCM.00549-16.
8. Subramony A, et al. J Pediatr. 2016; doi:10.1016/j.jpeds. 2016.02.050.
9. Echavarria M, et al. (2018) Journal of Clinical Virology. 108:90.

* Data generated using previous versions of this product.

Product availability varies by country. Consult your bioMérieux representative.